1. |
BommaReddy RR, Patel R, Smalley T, et al. Effects of atypical protein kinase C inhibitor (DNDA) on lung cancer proliferation and migration by PKC-ι/FAK ubiquitination through the Cbl-b pathway. Onco Targets Ther, 2020, 13: 1661-1676.
|
2. |
Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol, 2018, 48: 36-52.
|
3. |
Li M, Zhao Y, He J, et al. Protein kinase C theta inhibition attenuates lipopolysaccharide-induced acute lung injury through notch signaling pathway via suppressing Th17 cell response in mice. Inflammation, 2019, 42(6): 1980-1989.
|
4. |
Tsai JY, Rédei D, Hohmann J, et al. 12-deoxyphorbol esters induce growth arrest and apoptosis in human lung cancer A549 cells via activation of PKC-δ/PKD/ERK signaling pathway. Int J Mol Sci, 2020, 21(20): 7579.
|
5. |
Leskow FC, Krasnapolski MA, Urtreger AJ. The pros and cons of targeting protein kinase C (PKC) in the management of cancer patients. Curr Pharm Biotechnol, 2011, 12(11): 1961-73.
|
6. |
Mondrinos MJ, Kennedy PA, Lyons M, et al. Protein kinase C and acute respiratory distress syndrome. Shock, 2013, 39(6): 467-479.
|
7. |
Newton AC. Protein kinase C: perfectly balanced. Crit Rev Biochem Mol Biol, 2018, 53(2): 208-230.
|
8. |
Reyland ME, Jones DN. Multifunctional roles of PKCδ: opportunities for targeted therapy in human disease. Pharmacol Ther, 2016, 165: 1-13.
|
9. |
Singh RM, Cummings E, Pantos C, et al. Protein kinase C and cardiac dysfunction: a review. Heart Fail Rev, 2017, 22(6): 843-859.
|
10. |
Basu A. The enigmatic protein kinase C-eta. Cancers (Basel), 2019, 11(2): 214.
|
11. |
Fan CF, Li Y, Jia J. Protein kinase Cs in lung cancer: a promising target for therapies. J Cancer Res Ther, 2013, 9 Suppl 2: S74-S79.
|
12. |
Kim H, Zhao J, Zhang Q, et al. δV1-1 reduces pulmonary ischemia reperfusion-induced lung injury by inhibiting necrosis and mitochondrial localization of PKCδ and p53. Am J Transplant, 2016, 16(1): 83-98.
|
13. |
Wang SB, Ye Q, Tu JW, et al. Transient cerebral ischemia/reperfusion-induced acute lung injury in rats associated with protein kinase C alpha expression. Int J Clin Exp Pathol, 2018, 11(7): 3487-3493.
|
14. |
Shologu N, Scully M, Laffey JG, et al. Human mesenchymal stem cell secretome from bone marrow or adipose-derived tissue sources for treatment of hypoxia-induced pulmonary epithelial injury. Int J Mol Sci, 2018, 19(10): 2996.
|
15. |
Magnani ND, Dada LA, Queisser MA, et al. HIF and HOIL-1L-mediated PKCζ degradation stabilizes plasma membrane Na, K-ATPase to protect against hypoxia-induced lung injury. Proc Natl Acad Sci U S A, 2017, 114(47): E10178-E10186.
|
16. |
Kilpatrick LE, Standage SW, Li H, et al. Protection against sepsis-induced lung injury by selective inhibition of protein kinase C-δ (δ-PKC). J Leukoc Biol, 2011, 89(1): 3-10.
|
17. |
Liverani E, Mondrinos MJ, Sun S, et al. Role of protein kinase C-delta in regulating platelet activation and platelet-leukocyte interaction during sepsis. PLoS One, 2018, 13(4): e0195379.
|
18. |
Zhou HS, Li M, Sui BD, et al. Lipopolysaccharide impairs permeability of pulmonary microvascular endothelial cells via Connexin40. Microvasc Res, 2018, 115: 58-67.
|
19. |
Xie L, Chiang ET, Wu X, et al. Regulation of thrombin-induced lung endothelial cell barrier disruption by protein kinase C Delta. PLoS One, 2016, 11(7): e0158865.
|
20. |
Lee S, Ro H, In HJ, et al. Fisetin inhibits TNF-α/NF-κB-induced IL-8 expression by targeting PKCδ in human airway epithelial cells. Cytokine, 2018, 108: 247-254.
|
21. |
Lee J, Taneja V, Vassallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res, 2012, 91(2): 142-149.
|
22. |
Dianat M, Radan M, Badavi M, et al. Crocin attenuates cigarette smoke-induced lung injury and cardiac dysfunction by anti-oxidative effects: the role of Nrf2 antioxidant system in preventing oxidative stress. Respir Res, 2018, 19(1): 58.
|
23. |
Hsu HT, Tseng YT, Wong WJ, et al. Resveratrol prevents nanoparticles-induced inflammation and oxidative stress via downregulation of PKC-α and NADPH oxidase in lung epithelial A549 cells. BMC Complement Altern Med, 2018, 18(1): 211.
|
24. |
Wyatt TA, Slager RE, Heires AJ, et al. Sequential activation of protein kinase C isoforms by organic dust is mediated by tumor necrosis factor. Am J Respir Cell Mol Biol, 2010, 42(6): 706-715.
|
25. |
Schneberger D, DeVasure JM, Kirychuk SA, et al. Organic barn dust inhibits surfactant protein D production through protein kinase-C alpha dependent increase of GPR116. PLoS One, 2018, 13(12): e0208597.
|
26. |
Natarajan K, Gottipati KR, Berhane K, et al. Proteases and oxidant stress control organic dust induction of inflammatory gene expression in lung epithelial cells. Respir Res, 2016, 17(1): 137.
|
27. |
Zhan X, Zhang W, Sun T, et al. Bulleyaconitine a effectively relieves allergic lung inflammation in a murine asthmatic model. Med Sci Monit, 2019, 25: 1656-1662.
|
28. |
Qiao Y, Tam J, Tan S, et al. CD151, a laminin receptor showing increased expression in asthmatic patients, contributes to airway hyperresponsiveness through calcium signaling. J Allergy Clin Immunol, 2017, 139(1): 82-92.e5.
|
29. |
Madouri F, Chenuet P, Beuraud C, et al. Protein kinase C θ controls type 2 innate lymphoid cell and TH2 responses to house dust mite allergen. J Allergy Clin Immunol, 2017, 139(5): 1650-1666.
|
30. |
Wang J, Sun L, Nie Y, et al. Protein kinase C δ (PKCδ) attenuates bleomycin induced pulmonary fibrosis via inhibiting NF-κB signaling pathway. Front Physiol, 2020, 11: 367.
|
31. |
Garg R, Benedetti LG, Abera MB, et al. Protein kinase C and cancer: what we know and what we do not. Oncogene, 2014, 33(45): 5225-5237.
|
32. |
Garg R, Cooke M, Benavides F, et al. PKCε is required for KRAS-driven lung tumorigenesis. Cancer Res, 2020, 80(23): 5166-5173.
|
33. |
Casado-Medrano V, Barrio-Real L, Wang A, et al. Distinctive requirement of PKCε in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells. Oncogene, 2019, 38(27): 5396-5412.
|
34. |
Tzeng HT, Li TH, Tang YA, et al. Phosphorylation of Rab37 by protein kinase C alpha inhibits the exocytosis function and metastasis suppression activity of Rab37. Oncotarget, 2017, 8(65): 108556-108570.
|
35. |
Arencibia JM, Fröhner W, Krupa M, et al. An allosteric inhibitor scaffold targeting the PIF-pocket of atypical protein kinase C isoforms. ACS Chem Biol, 2017, 12(2): 564-573.
|
36. |
Lee PC, Fang YF, Yamaguchi H, et al. Targeting PKCδ as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell, 2018, 34(6): 954-969.e4.
|
37. |
Antal CE, Hudson AM, Kang E, et al. Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell, 2015, 160(3): 489-502.
|
38. |
Zhou Q, Dai J, Chen T, et al. Downregulation of PKCζ/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion. Cell Signal, 2017, 38: 49-59.
|
39. |
Cai X, Zhu H, Li Y. PKCζ, MMP-2 and MMP-9 expression in lung adenocarcinoma and association with a metastatic phenotype. Mol Med Rep, 2017, 16(6): 8301-8306.
|
40. |
Halvorsen AR, Haugen MH, Öjlert ÅK, et al. Protein kinase C isozymes associated with relapse free survival in non-small cell lung cancer patients. Front Oncol, 2020, 10: 590755.
|